|RxNews Recap for Monday 01-04-10|
|By Mary Davila|
|Monday, 04 January 2010 18:19|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Abbott (NYSE:ABT) will announce its fourth-quarter and full-year 2009 financial results on Wednesday, Jan. 27, 2010, before the market opens.
Antigenics Inc. (NASDAQ:AGEN) announced the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the “Staff”) on December 30, 2009 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Requirement”) because the bid price for the company’s common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has acquired Fidia Advanced Biopolymers, s.r.l. (“FAB”), a wholly-owned subsidiary of privately held Italian pharmaceutical company, Fidia Farmaceutici S.p.A. FAB provides hyaluronic acid-based (“HA”) products in several therapeutic areas including for the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled “Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens,” has been granted and will be issued as patent #1032417.
Anesiva, Inc. (Nasdaq: ANSV) announced today that it was unable to satisfy the closing conditions set forth in the Agreement and Plan of Merge, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation, a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto (the "Merger Agreement").
Alcon, Inc. (NYSE: ACL) announced that Novartis AG (NYSE: NVS) has exercised its option to purchase the remaining shares in Alcon owned by Nestle S.A. at a weighted average price of US$180 per share in cash.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming JPMorgan Healthcare Conference on Monday, January 11, 2010 at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, CA.
ArthroCare Corp. (Pink Sheets: ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, announced today it will present during the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.
Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the Goldman Sachs Healthcare CEOs Unscripted 2010: A View from the Top will be webcast live, via the internet, on Wednesday, January 6, 2010 at 4:15 p.m. EST.
Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced a series of measures adopted to strengthen the Company's corporate governance in compliance with the listing requirements of a senior U.S. exchange.
Biogen Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced that James C. Mullen, President and Chief Executive Officer, will retire from his position effective June 8, 2010.
Biogen Idec (NASDAQ:BIIB) today announced the appointment of Caroline Dorsa, Executive Vice President and Chief Financial Officer of Public Service Enterprise Group (PSEG) and former Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., to its Board of Directors. Ms. Dorsa fills a vacancy on the Board.
Commonwealth Biotechnologies, Inc. (“CBI”) (NASDAQ Capital Market: CBTE) is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL Biochem and its associated businesses (collectively the “GL Group”), the largest global supplier of research-grade peptide products and peptide reagents.
Emergent Health Corp. (Other OTC: EMGED) FINRA has received the necessary documentation to process the 11-10 forward split, payable upon surrender of old certificates for Emergent Health Corp (the “Company”).
Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2010 Third Quarter financial results before the U.S. stock market opens on Tuesday, January 19, 2010.
Levi & Korsinsky is investigating the Board of Directors of BioForm Medical, Inc. (“BioForm” or the “Company”) (NasdaqGM: BFRM) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Merz Pharma Group ("Merz Pharma").
Novartis AG (NYSE: NVS) announced today that it had exercised its option to purchase the remaining shares in Alcon, Inc. (NYSE: ACL) owned by Nestle S.A. at a weighted average price of US$180 per share in cash.
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Osteologix, Inc. (OTCBB: OLGX) today announced that it has entered into a securities purchase agreement for a $1 million private placement of its common stock.
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and their environment, today announced that the Company will present at the JP Morgan Healthcare Conference on Monday, January 11, 2010, at 4:30 pm Pacific Time at the Westin St Francis Hotel in San Francisco.
USANA Health Sciences, Inc. (NASDAQ:USNA) is proud to announce its partnership with fitness expert and celebrity trainer Kathy Kaehler.